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Cedars Sinai Medical Center, Los Angeles, California. 
e used quantitative coronary angiography to study 
results of 308 nm excimer laser coronary angioplasty 
(ELCA). Percutaneous ELCA was performed through a I,6 
mm diameter over-the-wire catheter having a concentrlc 
array of twelve quartz fibers. 22 patients had total or 
sub-total occlusions (Group l), 26 patients had milder 
stenoses (Group 2), and two patients were excluded due 
to technically oor angtograms, Following ELCA the mean 
stenosis minima B diameter in Group 1 changed from 
0.2tO.l mm to 1.620.6 mm (p < ,001). In contrast, 
diameter improved by only 0.4 mm, from 1.1kO.2 to 
l.StG.3 (p < ,Ol) in Group 2. The laser procedure was 
followed by balloon angioplasty in 16 patients from 
Group 1 and 22 patients from Group 2, Increasing yntn 
diameter from 1.5&0.5 to 2.OkO.5 mm (p 4 0.01). 
remaining 10 pattents with only ELCA were left with a 
eter of 1.61tO.3 mm. 
The mean luminal diameter following ELCA 
onds to the diameter of the laser 
oon angioplasty further improves the 
lumlnal diameter following laser procedure. A limiting 
factor with ELCA is that the current laser catheter size 
of 1.6 mm does not generally create a large enough 
lumen, requiring subsequent balloon angioplasty. A 
larger laser catheter could potentially be used without 
adjunctive balloon angioplasty. 
FACC, Mt. Sinai‘ ical Center, NewYork, NY 
were measured and the results summarized kx!low(m?m+SD): 
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ATRIAL BKRWRETIC PEPTIDE, ARGININE VASOPFWSIN AND 
RENAL FUNCTION DURING PERCUTANEOUS SVENOUS MIT 
vALwLoPLA8TY 
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msro Takaku, M.D., Morgan Fu, M.D., 
Kanji Inoue, M.D., Jui-Sung Huapg, 
M.D., F.A.C.C., Ka$wa Koheei Hospital and 3rd Dept of 
Int Med, University of Tokyo, Japan. 
To assess the pathophysiological significance of atri- 
al nattiuretic peptide (AN?) in water and elect yte 
metabolism, and to study the mechaaism of poets iaeuro- 
tomy sygldrome, the chaqes in plasma levels of ANP, argi- 
nine vasopresain (AVP), plasma renio activity (PRA), 
plasma aldoaterone concentration (PAC) and renal function 
were studied in 11 patients with mitral stenosis who 
underwent percutaneous mitral valvuPoplasty (PTMV). Ir 
mediately after PTMV, plasma ANP levels decreased(216’47 
vs 1382 51 p&al, mean+SEM) with a concomitant fall in 
mean pressure in the LA, the PA and the RA, The mean 
plasma AVP levela, showed a transient increase after PTMV 
(pt0.05). PTW waa accompanied by a significant increase 
in PRA, PAC, and a significant decrease in glomerular 
filtration rate (8927 vs 652 5 mUmin, pcO.011, renal 
plasma flow (435258 vs 305333 ml/min, pcO.Ol), urine 
flow (2.320.5 vs 1.0+0.2 mUmin, p<O.Ol) and urinary 
sodium excretion II62243 vs 732 13 ~mol/min, ~~0.05). 
30 fain after PTMV. 
These results suggest that B3t IY 
respond to a reduction in atria1 pressure to change ANP 
secretion, which directly or indirectly regulates water 
and sodium metabolism, 2) excessive AVP secretion leading 
to the post-commissurotomy syndrome is not linked to an 
abrupt reduction in atria1 preA;sure itself. 
